Catalent Email Format

Pharmaceutical Manufacturing
10,001-25,000 employees
Tampa, FL, USA

Catalent is a global contract development and manufacturing organization (CDMO) that partners with pharma, biotech, and consumer health companies to develop, manufacture, and deliver pharmaceutical products worldwide.

Find contacts at Catalent

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@catalent.com

Company Overview

Industry
Pharmaceutical Manufacturing
Founded
2007
Headquarters
Tampa, FL, USA
Revenue
$10B-$25B
FUNDING Stage
Public
Key Executives
Alessandro Maselli (President & Chief Executive Officer), Matti Masanovich (Senior Vice President & Chief Financial Officer), Tom Hawkeswood (Senior Vice President, Global Operations)

Tech Stack

HighByte Intelligence Hub

Industrial DataOps / Digital Transformation

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Catalent?

Catalent uses the first.last format, so Jane Smith would be jane.smith@catalent.com.

What is Catalent's Zydis technology used for?

Catalent's Zydis technology is a freeze-dried orally disintegrating tablet (ODT) that dissolves almost instantly in the mouth without water. It is used in more than 35 FDA-approved and marketed products across pharma and OTC brands.

Who is the CEO of Catalent?

Alessandro Maselli serves as President and Chief Executive Officer of Catalent. He leads the company alongside CFO Matti Masanovich and SVP of Global Operations Tom Hawkeswood.

Which parent company owns Catalent as of 2026?

Catalent is a subsidiary of Novo Holdings A/S, which completed its acquisition of Catalent in December 2024 in an all-cash transaction valued at approximately 16.5 billion dollars. Catalent continues to operate as a leading global CDMO under Novo Holdings ownership.

How does Catalent's Biologics segment support drug development, and how can I find the right contact there?

Catalent's Biologics segment offers cell therapy, gene therapy, and fill/finish manufacturing services for biotech and pharma partners. Tools like Clay can help you identify and verify the right Catalent Biologics contact when building a targeted outreach list.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles